AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for U11/U12 small nuclear ribonucleoprotein 48 kDa protein

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6IEG0

UPID:

SNR48_HUMAN

Alternative names:

-

Alternative UPACC:

Q6IEG0; A8K8P4; Q14C91; Q5T339; Q5THM1; Q5THM2; Q96MK1

Background:

The U11/U12 small nuclear ribonucleoprotein 48 kDa protein, with UniProt accession Q6IEG0, plays a crucial role in the splicing mechanism of pre-mRNA, specifically in U12-type 5' splice site recognition. This process is vital for the accurate removal of introns from pre-mRNA, ensuring the correct assembly of mature mRNA molecules for protein synthesis.

Therapeutic significance:

Understanding the role of U11/U12 small nuclear ribonucleoprotein 48 kDa protein could open doors to potential therapeutic strategies. Its involvement in the fundamental process of spliceosome-mediated splicing highlights its potential as a target for modulating gene expression in various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.